1. |
Glauser T, Ben-Menachem E, Bourgeois B, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia, 2013, 54(3): 551-563.
|
2. |
Brodie MJ, Perucca E, Ryvlin P, et al. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology, 2007, 68(6): 402-408.
|
3. |
Wright C, Downing J, Mungall D, et al. Clinical pharmacology and pharmacokinetics of levetiracetam. Front Neurol, 2013, 4(4): 192.
|
4. |
Bodalia PN, Grosso AM, Sofat R, et al. Comparative efficacy and tolerability of anti-epileptic drugs for refractory focal epilepsy: systematic review and network meta-analysis reveals the need for long term comparator trials. Br J Clin Pharmacol, 2013, 76(5): 649-667.
|
5. |
Pohlmann-Eden B, Marson AG, Noack-Rink M, et al. Comparative effectiveness of levetiracetam, valproate and carbamazepine among elderly patients with newly diagnosed epilepsy: subgroup analysis of the randomized, unblinded KOMET study. BMC Neurol, 2016, 16(1): 149.
|
6. |
Snoeck E, Stockis A. Dose-response population analysis of levetiracetam add-on treatment in refractory epileptic patients with partial onset seizures. Epilepsy Res, 2007, 73(3): 284-291.
|
7. |
Fang Y, Wu X, Xu L, et al. Randomized-controlled trials of levetiracetam as an adjunctive therapy in epilepsy of multiple seizure types. J Clin Neurosci, 2014, 21(1): 55-62.
|
8. |
Tsai JJ, Yen DJ, Hsih MS, et al. Efficacy and safety of levetiracetam (up to 2000 mg/day) in Taiwanese patients with refractory partial seizures: a multicenter, randomized, double-blind, placebo-controlled study. Epilepsia, 2006, 47(1): 72-81.
|
9. |
Zou XM, Chen JN, An DM, et al. Efficacy of low to moderate doses of oxcarbazepine in adult patients with newly diagnosed partial epilepsy. Seizure, 2015, 29(8): 81-85.
|
10. |
Shih JJ, Whitlock JB, Chimato N, et al. Epilepsy treatment in adults and adolescents: expert opinion, 2016. Epilepsy Behav, 2017. (2017-02-22)[2017-04-18]. doi: 10.1016/j.yebeh.2016.11.018.
|
11. |
Scott LJ. Lacosamide: a review in focal seizures in patients with epilepsy. Drugs, 2015, 75(18): 2143-2154.
|
12. |
Perucca E, Dulac O, Shorvon S, et al. Harnessing the clinical potential of antiepileptic drug therapy: dosage optimisation. CNS Drugs, 2001, 15(8): 609-621.
|
13. |
Brodie M, Barry SJ, Bamagous G, et al. Patterns of treatment response in newly diagnosed epilepsy. Neurology, 2012, 78(20): 1548-1554.
|
14. |
Brodie MJ, Barry SJ, Bamagous GA. Effect of dosage failed of first antiepileptic drug on subsequent outcome. Epilepsia, 2013, 54(1): 194-198.
|
15. |
Beghi E, Gatti G, Tonini C, et al. Adjunctive therapyversus alternative monotherapy in patients with partial epilepsy failing on a single drug: a multicentre, randomised, pragmatic controlled trial. Epilepsy Res, 2003, 57(1): 1-13.
|
16. |
Perucca E. Overtreatment in epilepsy: adverse Consequences and mechanisms. Epilepsy Res, 2002, 52(1): 25-33.
|
17. |
Ceylan M, Yalcin A, Bayraktutan OF, et al. Effects of levetiracetam monotherapy on sperm parameters and sex hormones: data from newly diagnosed patients with epilepsy. Seizure, 2016, 41: 70-74. doi: 10.1016/j.seizure.2016.06.001.
|
18. |
Stephen LJ, Kelly K, Parker P, et al. Levetiracetam monotherapy--outcomes from an epilepsy clinic. Seizure, 2011, 20(7): 554-557.
|
19. |
Kang BS, Moon HJ, Kim YS, et al. The long-term efficacy and safety of levetiracetam in a tertiary epilepsy centre. Epileptic Disord, 2013, 15(3): 302-310.
|
20. |
Xiao Z, Li JM, Wang XF, et al. Efficacy and safety of levetiracetam (3, 000 mg/day) as an adjunctive therapy in Chinese patients with refractory partial seizures. Eur Neurol, 2009, 61(4): 233-239.
|
21. |
Beran RG, Berkovic SF, Black AB, et al. Efficacy and safety of levetiracetam 1000-3000 mg/day in patients with refractory partial-onset seizures: a multicenter, open-label single-arm study. Epilepsy Res, 2005, 63(1): 1-9.
|
22. |
Bhoi SK, Kalita J, Misra UK. Skin rash following levetiracetam. Seizure, 2016, 37: 45-47. doi: 10.1016/j.seizure.2016.02.014.
|
23. |
Shahbaz N, Younus SM, Khan SA, et al. Levetiracetam induced increase in creatine phosphokinase levels. J Coll Physicians Surg Pak, 2017, 27(3): S63-s64.
|
24. |
Alkhotani A, Mclachlan RS. Levetiracetam induced angioedema in a patient with previous anticonvulsant hypersensitivity reaction to phenytoin and lamotrigine. Seizure, 2012, 21(5): 407-408.
|
25. |
Aikiä M, Kälviäinen R, Mervaala E, et al. Predictors of seizure outcome in newly diagnosed partial epilepsy: memory performance as a prognostic factor. Epilepsy Res, 1999, 37(2): 159-167.
|